Jan 28, 2021
CASI Pharmaceuticals Partner, BioInvent, Presents Phase I/IIA Data That Suggests BI-1206 Restores Activity Of Rituximab In Relapsed Non-Hodgkin's Lymphoma Patients
Jun 22, 2020
BioInvent and Transgene's BT-001 Achieves Outstanding Tumor Cure Rates in Preclinical Models
May 15, 2020
BioInvent Expands Anti-TNFR2 Program by Selecting Second Monoclonal Antibody for Further Development
Apr 08, 2020
BioInvent: Annual Report 2019
Mar 03, 2020
BioInvent and Transgene to Present Data on BT-001, an Oncolytic Virus Encoding for an Anti-CTLA4 Antibody, at Upcoming Congresses
Feb 27, 2020
BioInvent Financial Statement January 1 - December 31, 2019
Feb 24, 2020
Invitation to Presentation of BioInvent's Fourth Quarter Report 2019 on February 27, 2020
Dec 23, 2019
BioInvent Announces Selection of Second Target and Extension of the Research Collaboration and License Agreement With Pfizer Inc.
Dec 18, 2019
BioInvent Has Entered Into a Clinical Trial Collaboration and Supply Agreement to Evaluate BI-1206 in Combination With KEYTRUDA® in Advanced Solid Tumors
Nov 08, 2019
BioInvent to Present BI-1206 Preclinical Data in Mantle Cell lymphoma at ASH 2019
Oct 23, 2019
BioInvent Signs Manufacturing Agreement With Cancer Research UK Expected to Generate Approximately SEK 30 Million (~$3 Million)
Aug 22, 2019
BioInvent: Interim Report January 1 - June 30, 2019
Aug 21, 2019
BioInvent Will Conduct Phase l/lla Trial With BI-1206 in Combination With Pembrolizumab (Keytruda) in Solid Tumors
Aug 20, 2019
BioInvent's Partner Oxurion NV has Reported Topline Month 3 Results of Phase lla Study Evaluating THR-317 (anti-PLGF), in Combination With Ranibizumab, for DME
Aug 15, 2019
USPTO Intends to Grant BioInvent Patent Relating to BI-1206
Aug 14, 2019
Invitation to Presentation of BioInvent's Interim Report Q2-2019 on August 22, 2019
Jul 31, 2019
BioInvent Announces Selection of First Target Discovered by BioInvent's Proprietary F.I.R.S.TTM Technology Platform Under Collaboration With Pfizer Inc.
Jul 04, 2019
BioInvent Receives Milestone Payment Related to TAK-169 Investigational New Drug Application
Jun 12, 2019
BioInvent Publishes First Clinical Data From BI-1206 Phase l/lla Trials
Jun 03, 2019
BioInvent Submits IND for Phase I/IIa Trial of Anti-FcgRIIB Antibody